How does IOOA's PB Ratio compare to its peers?

IOOA is good value based on its Price-To-Book Ratio (0.4x) compared to the peer average (0.7x).

How does IOOA's PB Ratio compare vs other companies in the DE Capital Markets Industry?

IOOA is good value based on its Price-To-Book Ratio (0.4x) compared to the German Capital Markets industry average (1.1x).

What is IOOA's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate IOOA's Price-To-Book Fair Ratio for valuation analysis.

What is the Fair Price of IOOA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate IOOA's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine [[statistical confidence]] in agreement.

IP Group (DB:IOOA) - Stock Price, News & Analysis

IOOA Stock Overview

A private equity and venture capital firm specializing in seed/startup, early venture, emerging growth, mature, mid venture, late venture, incubation, mezzanine in growth capital companies. More details

IOOA fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Revenue is forecast to grow 106.56% per year

Risk Analysis

Makes less than USD$1m in revenue (£-213M)

Currently unprofitable and not forecast to become profitable over the next 3 years

IP Group Plc Competitors

Deutsche Balaton

HMSE:BBHK

€175.4m

Deutsche Beteiligungs

XTRA:DBAN

€426.4m

AURELIUS Equity Opportunities SE KGaA

HMSE:AR4

€390.6m

MLP

XTRA:MLP

€640.5m

Price History & Performance

Summary of all time highs, changes and price drops for IP Group
Historical stock prices
Current Share Price	UK£0.50
52 Week High	UK£0.66
52 Week Low	UK£0.42
Beta	1.39
11 Month Change	-6.42%
3 Month Change	2.06%
1 Year Change	-17.33%
33 Year Change	-62.71%
5 Year Change	n/a
Change since IPO	-45.13%

Recent updates

Shareholder Returns

	IOOA	DE Capital Markets	DE Market
7D	-5.5%	-0.7%	0.8%
1Y	-17.3%	27.0%	9.1%

Return vs Industry: IOOA underperformed the German Capital Markets industry which returned 26.5% over the past year.

Return vs Market: IOOA underperformed the German Market which returned 8.5% over the past year.

Price Volatility

Is IOOA's price volatile compared to industry and market?
IOOA volatility
IOOA Average Weekly Movement	6.2%
Capital Markets Industry Average Movement	4.2%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: IOOA has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: IOOA's weekly volatility (6%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2001	95	Greg Smith	www.ipgroupplc.com

IP Group Plc is a private equity and venture capital firm specializing in seed/startup, early venture, emerging growth, mature, mid venture, late venture, incubation, mezzanine in growth capital companies. It prefers to invest in energy, materials, healthcare, information technology, communication services, utilities, life sciences, deeptech, cleantech, chemicals, science and innovation companies. The firm prefers to invest in Europe.

IP Group Plc Fundamentals Summary

How do IP Group's earnings and revenue compare to its market cap?
IOOA fundamental statistics
Market cap	€510.68m
Earnings (TTM)	-€270.97m
Revenue (TTM)	n/a

-2.0x

P/S Ratio

-1.9x

P/E Ratio

Is IOOA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IOOA income statement (TTM)
Revenue	-UK£212.50m
Cost of Revenue	UK£0
Gross Profit	-UK£212.50m
Other Expenses	UK£13.80m
Earnings	-UK£226.30m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.23
Gross Margin	100.00%
Net Profit Margin	106.49%
Debt/Equity Ratio	14.2%

How did IOOA perform over the long term?

See historical performance and comparison

IOOA Stock Overview

Rewards

Risk Analysis

IP Group Plc Competitors

HMSE:BBHK

€175.4m

XTRA:DBAN

€426.4m

HMSE:AR4

€390.6m

XTRA:MLP

€640.5m

Price History & Performance

Recent News & Updates

Dr. Falk Pharma GmbH acquired Kynos Therapeutics Ltd from Epidarex Capital, IP Group Plc (LSE:IPO) and Scottish Investment Bank Limited.

Visa Inc. (NYSE:V) signed a definitive agreement to acquire Featurespace from from Chrysalis Investments Limited (LSE:CHRY), Highland Europe (UK) LLP, IP Group Plc (LSE:IPO), Insight Venture Management, LLC, MissionOG Capital, LLC, and TTV Capital LLC.

Visa Inc. (NYSE:V) signed a definitive agreement to acquire Featurespace from from Chrysalis Investments Limited (LSE:CHRY), Highland Europe (UK) LLP, IP Group Plc (LSE:IPO), Insight Venture Management, LLC, MissionOG Capital, LLC, and TTV Capital LLC.

First half 2024 earnings released: UK£0.11 loss per share (vs UK£0.053 loss in 1H 2023)

New major risk - Revenue and earnings growth

IP Group Plc to Report First Half, 2024 Results on Sep 17, 2024

Recent updates

Dr. Falk Pharma GmbH acquired Kynos Therapeutics Ltd from Epidarex Capital, IP Group Plc (LSE:IPO) and Scottish Investment Bank Limited.

Visa Inc. (NYSE:V) signed a definitive agreement to acquire Featurespace from from Chrysalis Investments Limited (LSE:CHRY), Highland Europe (UK) LLP, IP Group Plc (LSE:IPO), Insight Venture Management, LLC, MissionOG Capital, LLC, and TTV Capital LLC.

Visa Inc. (NYSE:V) signed a definitive agreement to acquire Featurespace from from Chrysalis Investments Limited (LSE:CHRY), Highland Europe (UK) LLP, IP Group Plc (LSE:IPO), Insight Venture Management, LLC, MissionOG Capital, LLC, and TTV Capital LLC.

First half 2024 earnings released: UK£0.11 loss per share (vs UK£0.053 loss in 1H 2023)

New major risk - Revenue and earnings growth

IP Group Plc to Report First Half, 2024 Results on Sep 17, 2024

New minor risk - Share price stability

Forcepoint LLC entered into a definitive agreement to acquire Garrison Technology Limited from IP Group Plc (LSE:IPO).

CEO & Executive Director recently sold €114k worth of stock

Full year 2023 earnings released: UK£0.17 loss per share (vs UK£0.33 loss in FY 2022)

New minor risk - Share price stability

Full year 2023 earnings released: UK£0.17 loss per share (vs UK£0.33 loss in FY 2022)

IP Group Plc, Annual General Meeting, Jun 12, 2024

New minor risk - Financial data availability

IP Group Plc to Report Fiscal Year 2023 Results on Mar 13, 2024

IP Group Plc (LSE:IPO) commences an Equity Buyback Plan for 103,677,065 shares, representing 10% of its issued share capital, under the authorization approved on June 15, 2023.

New minor risk - Share price stability

First half 2023 earnings released: UK£0.052 loss per share (vs UK£0.30 loss in 1H 2022)

IP Group Plc to Report First Half, 2023 Results on Aug 02, 2023

Full year 2022 earnings released: UK£0.33 loss per share (vs UK£0.42 profit in FY 2021)

IP Group Plc to Report Fiscal Year 2022 Results on Mar 08, 2023

Scaleworks Inc. acquired Import.io Ltd.

IP Group plc Appoints Anita Kidgellas an Independent Non-Executive Director

Insufficient new directors

Insider recently bought €51k worth of stock

Insufficient new directors

Ip Group plc Announces the Initiation of Its Phase 2B Trial of Mbs2320, Its Lead Drug in Rheumatoid Arthritis, with the First Patients Now Dosed

First half 2022 earnings released

IP Group Plc Declares an Interim Dividend in Respect of the Period from 1 January 2022 to 30 June 2022, Payable on or Around 19 September 2022

IP Group Plc to Report First Half, 2022 Results on Aug 03, 2022

IP Group Plc Launches 'Kiko Ventures' Platform to Deepen Its Support for Transformative Climate Technology

Investor sentiment improved over the past week

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

IP Group Plc to Report Fiscal Year 2021 Results on Mar 16, 2022

Investor sentiment deteriorated over the past week

Insider recently bought €72k worth of stock

Executive Officer recently bought €59k worth of stock

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

First half 2021 earnings released: EPS UK£0.11 (vs UK£0.011 in 1H 2020)

NeoGenomics Laboratories, Inc. completed the acquisition of remaining 88.95% stake in Inivata Limited from a group of sellers.

IP Group Plc Announces Inaugural Dividend, Payable on 16 June 2021

Full year 2020 earnings released: EPS UK£0.17 (vs UK£0.071 loss in FY 2019)

Athenex, Inc. (NasdaqGS:ATNX) acquired Kuur Therapeutics Limited.

Full year 2020 earnings released: EPS UK£0.17 (vs UK£0.071 loss in FY 2019)

Revenue beats expectations

IP Group Plc, Annual General Meeting, Jun 09, 2021

New 90-day high: €1.44

IP Group Plc to Report Fiscal Year 2020 Results on Mar 10, 2021

Centessa Pharmaceuticals Limited acquired ApcinteX from Medicxi Ventures (UK) LLP, Touchstone Innovations Plc, Cambridge Enterprise Seed Funds and IP Group Plc (LSE:IPO).

New 90-day high: €1.25

Shareholder Returns

Price Volatility

About the Company

IP Group Plc Fundamentals Summary

-2.0x

-1.9x

Earnings & Revenue